Teva settles U.S. states' generic drug price-fixing case
A multistate antitrust case over alleged generic drug price manipulation is moving toward resolution after Teva Pharmaceutical Industries reached an agreement in principle with most U.S. state plaintiffs. The litigation covers claims from 45 U.S. states, Washington, D.C., and two U.S. territories over alleged conduct tied to dozens of medicines and pricing increases dating back to 2012.
Highlights
- Teva agrees in principle to settle a major U.S. generic drug price-fixing lawsuit, with terms undisclosed, prompting a Connecticut court to put the case on hold.
- States allege Teva colluded to raise prices on about 112 generic drugs during 2013-2014, with increases on at least 86 drugs sometimes exceeding 1,000%.
- Two additional antitrust lawsuits against generic drugmakers remain active under Judge Michael Shea, maintaining ongoing legal scrutiny of the sector.
Settlement progress in Connecticut court
As reported by Reuters, Chief Judge Michael Shea of the federal court in Hartford, Connecticut, puts the case on hold on Monday after both sides reach an agreement in principle to settle, according to court records.Settlement terms are not disclosed. Teva does not immediately respond to requests for comment, and the office of Connecticut Attorney General William Tong, whose state leads the litigation, also does not immediately respond to similar requests.
Allegations and broader antitrust exposure
The states accuse Teva and other defendants of having in 2012 embarked on what they call one of the most egregious and damaging price-fixing conspiracies in U.S. history. They allege the companies agree to preserve their fair share of each generic drug market while raising prices on as many medicines as possible.The states say prices skyrocket in 2013 and 2014. They allege Teva significantly raises prices on about 112 different generic drugs and colludes with competitors to raise prices on at least 86 of them, in some cases by more than 1,000%.
Shea also oversees two other antitrust lawsuits brought by state attorneys general related to generic drugs, leaving broader legal scrutiny of the sector still in place.
Previously, we outlined the main factors behind Ambee Pharmaceuticals earnings as it posted weaker results while maintaining an FY26 cash dividend.